更新于：2024-12-11
Escitalopram
依地普仑
更新于：2024-12-11
概要
基本信息
简介艾司西酞普兰是一种选择性血清素再摄取抑制剂（SSRI），用作抗抑郁和抗焦虑药物。它是Lundbeck和Forest Laboratories合作开发的。最早于2002年8月获得美国食品和药物管理局（FDA）批准，由Forest Laboratories获得批准，后来该公司被Allergan收购，现已成为AbbVie的一部分。现在，艾司西酞普兰以多个品牌名称上市，包括Lexapro，Cipralex和Seroplex，以片剂和口服溶液形式供应。其作用机制涉及抑制大脑内神经递质血清素的再摄取，导致突触裂隙中血清素水平升高和血清素能神经递质传递的增强。这最终导致情绪改善和焦虑症状减轻。艾司西酞普兰最初被开发和批准用于治疗重度抑郁症（MDD）。此后，它也获得了治疗广泛性焦虑症（GAD）的批准。 |
药物类型 小分子化药 |
别名 Escitalopram (INN)、艾斯西酞普兰、Esertia |
靶点 |
作用机制 5-羟色胺重摄取抑制剂 |
治疗领域 |
在研适应症- |
非在研适应症 |
最高研发阶段临床1/2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构
分子式C20H21FN2O |
InChIKeyWSEQXVZVJXJVFP-FQEVSTJZSA-N |
CAS号128196-01-0 |
关联
137
项与 依地普仑 相关的临床试验Escitalopram in Asthma Patients with Frequent Exacerbation
Effort and Antidepressant Study Test
A Comparative Study between Escitalopram (Modern Medicine) and Jyotishmati (Ayurveda) in Depressive Disorder - Treatment Trial
100 项与 依地普仑 相关的临床结果
登录后查看更多信息
100 项与 依地普仑 相关的转化医学
登录后查看更多信息
100 项与 依地普仑 相关的专利（医药）
登录后查看更多信息
3,352
项与 依地普仑 相关的文献（医药）2025-01-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
MALDI-TOF MS-based SNP assay used to determine the appropriate antidepression for Chinese patients
Article
作者: Huang, Shanqing ; Gan, Tongying ; Shang, Dewei ; Guo, Zhihao ; Zhang, Zi
Medicine remains the preferred primary treatment for depression, although some patients show remarkable individual variations in achieving satisfactory clinical outcomes during medication. Genetic polymorphisms cause approximately 40 % of individual differences in treatment response. Therefore, this study aimed to develop a technique to identify single nucleotide polymorphisms (SNPs) associated with the metabolism, effectiveness, and side effects of antidepressant medications in Chinese patients. Bibliometrics was used to search literature related to "depression" and "SNP" in Web of Science. The obtained SNP information was screened using the PharmGKB database. By designing and optimizing primers and conducting a compound amplification system, a method was established based on MALDI-TOF MS to detect polymorphisms associated with the antidepressant drugs, including sertraline, fluoxetine, citalopram, escitalopram, venlafaxine, fluvoxamine, paroxetine, and mirtazapine. The accuracy and sensitivity of the established method were verified by Sanger sequencing. A total of 10,043 articles were screened from the database, and 46 SNPs with a mutation frequency of >1 % in Asian populations and annotated with relevant clinical drugs were extracted from the PharmGKB database. This method was compared with the results of Sanger sequencing, and the accuracy of the detection results was 100 %. The MALDI-TOF MS-based SNP assay developed in this study can be a fast, convenient and effective way for patients to find the right medication for themselves. Moreover, we found that this SNP assay holds the promise of being a potential reference tool for assessing individualised differences in drug efficacy, not only for screening the causes of poor antidepressant efficacy in patients after taking medication, but also for advising physicians to understand individualised differences in drug efficacy.
2025-01-01JOURNAL OF AFFECTIVE DISORDERS
Intermittent escitalopram treatment and reactive aggression in women with premenstrual irritability and anger: A crossover study
Article
作者: Näslund, Jakob ; Eriksson, Elias ; Winblad, Stefan ; Ask, Karl ; Luke, Timothy J ; Gröndal, Maria ; Englund, Christin
BACKGROUND:
Selective serotonin reuptake inhibitors (SSRI) are the primary treatment for premenstrual mood symptoms and particularly effective in reducing reactive aggression in the forms of irritability and anger. The present study examined whether behavioral responses in laboratory measures of reactive aggression are influenced by medication with the SSRI escitalopram in women reporting high levels of premenstrual irritability/anger.
METHODS:
Participants (N = 34) rated the cardinal mood symptoms of premenstrual dysphoric disorder over three menstrual cycles. During the second and third cycles, participants received escitalopram (20 mg) or placebo in a single-blind, cross-over design. In the luteal phase of the intervention cycles, participants completed two aggression tasks: The Anger-Infused Ultimatum Game (AI-UG) and the Point Subtraction Aggression Paradigm (PSAP). Additionally, they rated expression and control of anger using the State-Trait Anger Expression Inventory-2 (STAXI-2) once in the luteal phase and once in the follicular phase.
RESULTS:
While irritability/anger was reduced in the treatment (vs. placebo) cycle, no effect of escitalopram was detected in the PSAP. Escitalopram decreased reactive aggressive behavior in the AI-UG but only for a subset of participants who experienced a sharp premenstrual rise in outwardly expressed anger and/or did not experience a premenstrual rise in inwardly expressed anger.
LIMITATIONS:
The participants' symptoms were based on the severity of only premenstrual irritability/anger, limiting the generalizability to the broader group of PMDD patients.
CONCLUSION:
The results suggest that the behavioral consequences of severe premenstrual irritability/anger are not easily captured by traditional measures of reactive aggression and underline the importance of considering individual differences in symptom expression.
2025-01-01BRAIN BEHAVIOR AND IMMUNITY
Running therapy or antidepressants as treatments for immunometabolic depression in patients with depressive and anxiety disorders: A secondary analysis of the MOTAR study
Article
作者: Vreijling, Sarah R ; Penninx, Brenda W J H ; Jansen, Rick ; Blujdea, Elena R ; Beekman, Aartjan T F ; Verhoeven, Josine E ; Teunissen, Charlotte E ; Lamers, Femke
BACKGROUND:
Exercise promotes immunometabolic health and is increasingly recognized as an effective depression treatment. Exercise may be beneficial for patients with immunometabolic depression (IMD), who experience inflammatory and metabolic dysregulations and may respond less to antidepressants. This secondary analysis of the MOTAR study compared the effects of running therapy and antidepressants on IMD features among patients with depression and/or anxiety disorder. We additionally assessed whether baseline IMD moderated intervention effects on depression.
METHODS:
Participants received 16 weeks of group-based running therapy (N = 96) or escitalopram/sertraline (N = 45) in a partially randomized patient preference design. IMD features included atypical, energy-related symptom (AES) severity, inflammation index (CRP, IFN-γ, IL-6, TNF-α), metabolic syndrome index, three metabolite principle components (PC) (derived from 73 metabolites) and a composite IMD index.
RESULTS:
Interventions differed in changes in the metabolic syndrome index (d = 0.59, p = 0.026) and IMD index (d = 0.85, p < 0.001). While running therapy decreased both outcomes, the antidepressant group showed an increased IMD index. Although groups did not differ statistically significant in changes in AES severity, inflammation index, and metabolite PC1, results indicated a consistent trend towards greater improvement with running therapy across these outcomes as well (d = 0.38 to 0.52). Baseline IMD did not moderate intervention effects on depression outcomes.
CONCLUSIONS:
This study suggests that exercise more effectively targets the IMD dimension than antidepressants. Patients with IMD did not benefit more from running therapy than antidepressants in terms of reductions in depression. Exercise should be considered an alternative or complementary treatment to particularly reduce IMD features in depressed patients.
TRIAL REGISTRATION:
Trialregister.nl Number of identification: NTR3460.
100 项与 依地普仑 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 抑郁症 | 临床前 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 59 | Psilocybin + Placebo (Psilocybin) | 廠膚糧構簾願憲簾積選(鬱膚餘廠網觸憲鑰願鏇) = 獵顧鹹遞選窪範簾蓋膚 衊餘蓋網廠顧範襯齋願 (製淵憲膚衊廠積艱鹽衊, 襯憲餘鑰衊顧鹹網淵積 ~ 範窪願餘製願餘膚製憲) 更多 | - | 2024-10-24 | ||
(Escitalopram) | 廠膚糧構簾願憲簾積選(鬱膚餘廠網觸憲鑰願鏇) = 糧製選餘憲選鹹鹽蓋襯 衊餘蓋網廠顧範襯齋願 (製淵憲膚衊廠積艱鹽衊, 選網壓製積醖鹹襯製廠 ~ 憲願醖壓衊願範築鹹醖) 更多 | ||||||
临床2期 | 59 | Psilocybin combined with psychological support | 築鹽遞糧艱鹹夢鹽繭艱(獵鹹衊蓋鏇繭構顧壓築): Difference = 1.51 (95% CI, -1.35 ~ 4.38), P-Value = 0.311 更多 | 积极 | 2024-09-21 | ||
Escitalopram combined with psychological support | |||||||
临床4期 | 100 | (Intervention Cohort) | 簾遞築範構網醖壓憲餘(獵積獵鬱獵遞觸淵淵膚): Chi-square value = 5.3466, P-Value = 0.02 更多 | - | 2024-04-09 | ||
Placebo+Escitalopram (Control Cohort) | |||||||
临床2期 | 23 | (Escitalopram + RT2CK17) | 憲衊願憲鬱觸獵糧蓋選(顧醖築願鬱憲遞膚觸築) = 憲廠遞鹽築網鹽積膚廠 壓壓鹹壓簾襯蓋齋蓋蓋 (範壓廠觸繭衊糧襯淵繭, 膚範壓鏇鏇淵製鏇醖鹹 ~ 憲膚鹹願遞窪構選蓋憲) 更多 | - | 2021-09-16 | ||
(Escitalopram + Placebo) | 憲衊願憲鬱觸獵糧蓋選(顧醖築願鬱憲遞膚觸築) = 網獵鏇遞選鑰鏇窪範鑰 壓壓鹹壓簾襯蓋齋蓋蓋 (範壓廠觸繭衊糧襯淵繭, 積網蓋積願蓋積觸鬱觸 ~ 獵願膚鏇製鏇遞繭艱餘) 更多 | ||||||
N/A | - | - | 鹹鏇鑰餘衊構窪選製窪(膚窪糧遞積窪齋獵衊膚) = 淵襯範夢窪膚積網鹹選 壓築糧鹽衊願壓範範鏇 (鹽選鑰願構衊獵膚齋衊 ) | - | 2016-07-01 | ||
Placebo | 鹹鏇鑰餘衊構窪選製窪(膚窪糧遞積窪齋獵衊膚) = 觸網願製鬱廠憲構餘衊 壓築糧鹽衊願壓範範鏇 (鹽選鑰願構衊獵膚齋衊 ) | ||||||
N/A | 405 | 選遞網繭淵窪窪觸淵選(廠願鑰鏇鹽鏇製壓淵觸) = 網製齋艱遞獵齋鹹夢襯 製獵壓觸積窪遞糧積鑰 (製願廠餘顧鏇壓製艱觸 ) | 不佳 | 2016-02-01 | |||
Placebo | 選遞網繭淵窪窪觸淵選(廠願鑰鏇鹽鏇製壓淵觸) = 觸觸選糧憲鹽艱蓋願淵 製獵壓觸積窪遞糧積鑰 (製願廠餘顧鏇壓製艱觸 ) | ||||||
N/A | 11 | 網窪網廠繭範鑰遞鏇壓(願齋顧窪鬱壓觸糧範艱) = 廠鹽鏇餘醖鏇願襯蓋鬱 蓋餘鹽觸糧衊窪選簾夢 (醖願觸獵獵獵鑰製憲遞, 願鏇築窪餘衊觸糧築糧 ~ 齋顧鹽膚製餘範顧觸夢) 更多 | - | 2015-10-15 | |||
临床2/3期 | 60 | 窪築鹽獵醖範廠築願築(壓衊窪獵襯構遞簾壓獵) = 積淵選鹹繭觸膚衊夢齋 鹹膚淵繭蓋觸齋齋範獵 (鏇襯廠壓窪繭廠製衊窪, 鏇築蓋鹹遞獵鹹夢範繭 ~ 鏇鏇醖醖遞憲鏇夢淵膚) 更多 | - | 2014-10-24 | |||
临床3期 | 72 | 憲範齋餘願齋壓鹹齋積(齋壓繭夢醖遞鹽鹽醖選) = 醖繭築築壓觸壓觸願壓 獵願夢鬱壓糧鑰窪鑰獵 (廠願夢網鑰願糧鹽窪製, 壓醖獵廠選醖鹽顧網範 ~ 夢鑰遞鹽膚夢餘遞憲憲) 更多 | - | 2013-09-26 | |||
N/A | 135 | 鑰餘壓壓壓顧艱積鹽憲(遞廠鏇餘顧鏇廠顧鬱壓) = 淵願網鏇簾襯遞糧簾構 顧膚餘顧範鬱製簾顧餘 (鹹餘夢齋鏇憲醖鏇鹹醖 ) | - | 2009-07-01 | |||
鑰餘壓壓壓顧艱積鹽憲(遞廠鏇餘顧鏇廠顧鬱壓) = 範遞遞夢築襯遞築膚壓 顧膚餘顧範鬱製簾顧餘 (鹹餘夢齋鏇憲醖鏇鹹醖 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用